Meta-Analysis of Soluble Suppression of Tumorigenicity-2 and Prognosis in Acute Heart Failure.

Aimo A; Vergaro G; Ripoli A; Bayes-Genis A; Pascual Figal DA; de Boer RA; Lassus J; Mebazaa A; Gayat E; Breidthardt T; Sabti Z; Mueller C; Brunner-La Rocca HP; Tang WH; Grodin JL; Zhang Y; Bettencourt P; Maisel AS; Passino C; Januzzi JL; Emdin M

doi:10.1016/j.jchf.2016.12.016

Back

Journal article

Meta-Analysis of Soluble Suppression of Tumorigenicity-2 and Prognosis in Acute Heart Failure.

Aimo A Scuola Superiore Sant'Anna, Pisa, Italy. Electronic address: albertoaimo@libero.it.
Vergaro G Scuola Superiore Sant'Anna, Pisa, Italy; Fondazione Toscana G. Monasterio, Pisa, Italy.
Ripoli A Fondazione Toscana G. Monasterio, Pisa, Italy.
Bayes-Genis A Hospital Universitari Germans Trias i Pujol, Barcelona, Spain.
Pascual Figal DA Hospital Universitario Arrixaca, University of Murcia, Murcia, Spain.
de Boer RA University Medical Center Groningen, Groningen, the Netherlands.
Lassus J Heart and Lung Center, Helsinki University Hospital and Helsinki University, Helsinki, Finland.
Mebazaa A INSERM U 942, Université Paris Diderot, APHP Hôpitaux Universitaires Saint Louis Lariboisière, Paris, France.
Gayat E INSERM U 942, Université Paris Diderot, APHP Hôpitaux Universitaires Saint Louis Lariboisière, Paris, France.
Breidthardt T Universitätsspital Basel, Basel, Switzerland.
Sabti Z Universitätsspital Basel, Basel, Switzerland.
Mueller C Universitätsspital Basel, Basel, Switzerland.
Brunner-La Rocca HP Department of Cardiology, Maastricht University Medical Centre, Maastricht, the Netherlands.
Tang WH Heart and Vascular Institute, Cleveland Clinic, Cleveland, Ohio.
Grodin JL Department of Internal Medicine, Division of Cardiology, University of Texas Southwestern Medical Center, Dallas, Texas.
Zhang Y Peking Union Medical College, Beijing, China.
Bettencourt P University of Porto Medical School, Porto, Portugal.
Maisel AS University of California, San Diego, School of Medicine, San Diego, California.
Passino C Scuola Superiore Sant'Anna, Pisa, Italy; Fondazione Toscana G. Monasterio, Pisa, Italy.
Januzzi JL Massachusetts General Hospital and Harvard Clinical Research Institute, Boston, Massachusetts.
Emdin M Scuola Superiore Sant'Anna, Pisa, Italy; Fondazione Toscana G. Monasterio, Pisa, Italy.

2017-02-13

Published in:

JACC. Heart failure. - 2017

Interleukin-1 Receptor-Like 1 Protein

English OBJECTIVES
The aim of this study was to perform a meta-analysis of currently available data regarding the prognostic significance of soluble suppression of tumorigenecity-2 (sST2) concentration in acute heart failure (AHF).

BACKGROUND
Concentration of sST2 may have prognostic value in AHF. A comprehensive assessment of all available studies regarding sST2 in AHF is lacking.

METHODS
Three databases (MEDLINE, Cochrane Library, and Scopus) were searched. Inclusion criteria were follow-up studies, papers published in English, enrollment of patients with AHF, and availability of median hazard ratios for all-cause death and other outcome measures, when available.

RESULTS
Ten studies were included, with a global population of 4,835 patients and a median follow-up duration of 13.5 months. The following global hazard ratios calculated for log2(sST2) were admission sST2 and all-cause death, 2.46 (95% confidence interval [CI]: 1.80 to 3.37; p < 0.001); discharge sST2 and all-cause death, 2.06 (95% CI: 1.37 to 3.11; p < 0.001); admission sST2 and cardiovascular death, 2.29 (95% CI: 1.41 to 3.73; p < 0.001); discharge sST2 and cardiovascular death, 2.20 (95% CI: 1.48 to 3.25; p < 0.001); admission sST2 and heart failure (HF) hospitalization, 1.21 (95% CI: 0.96 to 1.52; p = 0.060); discharge sST2 and HF hospitalization, 1.54 (95% CI: 1.03 to 2.32; p = 0.007); admission sST2 and all-cause death or HF hospitalization, 1.74 (95% CI: 1.24 to 2.45; p < 0.001); and discharge sST2 and all-cause death or HF hospitalization, 1.63 (95% CI: 1.14 to 2.33; p < 0.001).

CONCLUSIONS
Plasma sST2 has prognostic value with respect to all-cause and cardiovascular death as well as the composite outcome of all-cause death or HF hospitalization, with both admission and discharge values having prognostic efficacy. Discharge sST2, but not admission sST2, is predictive of HF rehospitalization during follow-up.

Language